• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.通过诱变获得的免疫原性变体对非免疫原性小鼠白血病的保护作用。
Proc Natl Acad Sci U S A. 1982 Aug;79(15):4718-22. doi: 10.1073/pnas.79.15.4718.
2
Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis.通过诱变获得的免疫原性变体对两种自发性小鼠白血病的保护作用。
J Exp Med. 1983 Jun 1;157(6):1992-2001. doi: 10.1084/jem.157.6.1992.
3
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。I. 同基因小鼠的排斥反应。
J Exp Med. 1980 Nov 1;152(5):1175-83. doi: 10.1084/jem.152.5.1175.
4
The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment.通过诱变处理获得的高免疫原性变体诱导对非免疫原性肿瘤增强的抗肿瘤作用。
Jpn J Cancer Res. 1988 Nov;79(11):1247-53. doi: 10.1111/j.1349-7006.1988.tb01551.x.
5
Tumour cell variants with increased immunogenicity obtained by mutagen treatment.通过诱变处理获得的具有增强免疫原性的肿瘤细胞变体。
Cancer Surv. 1985;4(1):135-48.
6
Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.通过对Lewis肺癌细胞系进行诱变获得的肿瘤细胞变体:同基因小鼠的免疫排斥反应。
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5282-5. doi: 10.1073/pnas.76.10.5282.
7
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。II. T淋巴细胞介导的细胞溶解作用。
J Exp Med. 1980 Nov 1;152(5):1184-93. doi: 10.1084/jem.152.5.1184.
8
Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.同基因小鼠排斥的畸胎瘤细胞变体:用这些变体免疫的小鼠对其他变体和原始恶性细胞系的保护作用。
Proc Natl Acad Sci U S A. 1978 Mar;75(3):1519-23. doi: 10.1073/pnas.75.3.1519.
9
Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.针对小鼠逆转录病毒诱导的同基因T细胞白血病,会产生不同的增殖性T细胞克隆型:病毒gp70抗原特异性MT4 +克隆和识别肿瘤特异性细胞表面抗原的Lyt-2 +溶细胞克隆。
J Immunol. 1985 Jul;135(1):703-13.
10
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。IV. 用细胞溶解T细胞克隆选择抗原缺失变体分析变体特异性抗原。
Eur J Immunol. 1982 May;12(5):406-12. doi: 10.1002/eji.1830120509.

引用本文的文献

1
Defining Immunogenic and Radioimmunogenic Tumors.定义免疫原性和放射免疫原性肿瘤。
Front Oncol. 2021 Mar 19;11:667075. doi: 10.3389/fonc.2021.667075. eCollection 2021.
2
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.儿童、青少年和青年癌症患者免疫治疗毒性的诊断、分级和管理。
Nat Rev Clin Oncol. 2021 Jul;18(7):435-453. doi: 10.1038/s41571-021-00474-4. Epub 2021 Feb 19.
3
Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.揭示肿瘤抗原全景:关于发现过程需了解的内容。
Cancers (Basel). 2020 Jun 23;12(6):1660. doi: 10.3390/cancers12061660.
4
Synergism of co-delivered nanosized antioxidants displayed enhanced anticancer efficacy in human colon cancer cell lines.共同递送的纳米级抗氧化剂的协同作用在人结肠癌细胞系中显示出增强的抗癌功效。
Bioact Mater. 2017 Mar 6;2(2):82-95. doi: 10.1016/j.bioactmat.2017.02.003. eCollection 2017 Jun.
5
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.肿瘤免疫疗法:药物诱导的新抗原(异种化)与免疫检查点抑制剂。
Oncotarget. 2017 Jun 20;8(25):41641-41669. doi: 10.18632/oncotarget.16335.
6
Impact of the immune system and immunotherapy in colorectal cancer.免疫系统及免疫疗法在结直肠癌中的影响
J Gastrointest Oncol. 2015 Apr;6(2):208-23. doi: 10.3978/j.issn.2078-6891.2014.077.
7
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.胶质母细胞瘤治疗的未来:标准治疗与免疫治疗的协同作用。
Cancers (Basel). 2014 Sep 29;6(4):1953-85. doi: 10.3390/cancers6041953.
8
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.诱导多能干细胞:癌症免疫疗法的挑战与机遇。
Front Immunol. 2014 Apr 17;5:176. doi: 10.3389/fimmu.2014.00176. eCollection 2014.
9
Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.肿瘤小鼠模型证实MAGE - A3癌症免疫疗法是持久抗肿瘤反应的有效诱导剂。
PLoS One. 2014 May 15;9(5):e94883. doi: 10.1371/journal.pone.0094883. eCollection 2014.
10
Developing effective tumor vaccines: basis, challenges and perspectives.开发有效的肿瘤疫苗:基础、挑战与展望
Front Med China. 2007 Feb;1(1):11-9. doi: 10.1007/s11684-007-0003-9. Epub 2007 Feb 1.

本文引用的文献

1
ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.莫洛尼氏因子诱导的淋巴瘤的抗原特性
J Natl Cancer Inst. 1964 Mar;32:547-68.
2
Immunity to methylcholanthrene-induced sarcomas.对甲基胆蒽诱导肉瘤的免疫性。
J Natl Cancer Inst. 1957 Jun;18(6):769-78.
3
Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus.用感染了弗氏病毒的相同肿瘤细胞免疫抑制移植的大鼠肿瘤。
J Natl Cancer Inst. 1970 Jan;44(1):11-9.
4
Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor.小鼠畸胎癌的免疫原性细胞变体可对原始的非免疫原性可移植肿瘤起到保护作用。
Eur J Cancer Clin Oncol. 1981 Oct;17(10):1083-7. doi: 10.1016/0014-2964(81)90292-9.
5
Interleukin-2 dependent culture of cytolytic T cell lines.细胞溶解性T细胞系的白细胞介素-2依赖性培养
Immunol Rev. 1981;54:81-109. doi: 10.1111/j.1600-065x.1981.tb00435.x.
6
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.癌症免疫学:寻找特异性——G. H. A. 克劳斯纪念讲座
Cancer Res. 1981 Feb;41(2):361-75.
7
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。II. T淋巴细胞介导的细胞溶解作用。
J Exp Med. 1980 Nov 1;152(5):1184-93. doi: 10.1084/jem.152.5.1184.
8
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。I. 同基因小鼠的排斥反应。
J Exp Med. 1980 Nov 1;152(5):1175-83. doi: 10.1084/jem.152.5.1175.
9
Quantitation and cloning of cytolytic T lymphocytes and their precursors.细胞溶解性T淋巴细胞及其前体的定量与克隆
Immunol Rev. 1980;51:93-123. doi: 10.1111/j.1600-065x.1980.tb00318.x.
10
Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.细胞毒性T淋巴细胞(CTL)对鼠肉瘤病毒诱导肿瘤的抗原特异性。II. 同基因肿瘤细胞体外刺激CTL前体细胞的克隆后代分析。
J Immunol. 1980 Apr;124(4):1627-34.

通过诱变获得的免疫原性变体对非免疫原性小鼠白血病的保护作用。

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

作者信息

Van Pel A, Boon T

出版信息

Proc Natl Acad Sci U S A. 1982 Aug;79(15):4718-22. doi: 10.1073/pnas.79.15.4718.

DOI:10.1073/pnas.79.15.4718
PMID:6981814
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC346748/
Abstract

The nonimmunogenic thymic leukemia TH, obtained in mouse strain CBA/Ht, was adapted to culture. By in vitro treatment of a clonal TH cell line with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine, stable variant cell clones (tum-) were obtained that elicited a rejection response in syngeneic mice. Mice that had rejected a tum- variant were partially protected against a challenge with the original tumor. When spleen cells of these animals were restimulated in vitro, cytolytic T cells were obtained that were directed against an antigen present on the original tumor. The existence of these cytolytic effectors was confirmed by clonal analysis of the cytolytic response. No immune protection against TH was observed in mice that had been immunized with irradiated cells of the original TH tumor. These results confirm that tum- variants can elicit a syngeneic rejection response against tumors that are apparently devoid of transplantation immunogenicity. The experimental conditions and the results make it likely but not certain that the tumor-associated antigen detected on leukemia TH was present on the primary tumor.

摘要

在CBA/Ht小鼠品系中获得的非免疫原性胸腺白血病TH被适应于培养。通过用诱变剂N-甲基-N'-硝基-N-亚硝基胍对克隆的TH细胞系进行体外处理,获得了稳定的变异细胞克隆(tum-),这些克隆在同基因小鼠中引发了排斥反应。排斥了tum-变异体的小鼠对原始肿瘤的攻击有部分保护作用。当这些动物的脾细胞在体外再次刺激时,获得了针对原始肿瘤上存在的一种抗原的细胞毒性T细胞。通过对细胞毒性反应的克隆分析证实了这些细胞毒性效应器的存在。在用原始TH肿瘤的照射细胞免疫的小鼠中未观察到对TH的免疫保护。这些结果证实,tum-变异体可以引发针对明显缺乏移植免疫原性的肿瘤的同基因排斥反应。实验条件和结果使得白血病TH上检测到的肿瘤相关抗原可能存在于原发性肿瘤上,但不能确定。